294877-41-1

Usage

Uses

Used in Organic Synthesis:
1-(4-BROMOPHENYL)-1H-PYRAZOLE-4-CARBALDEHYDE is used as a synthetic intermediate for the creation of various organic compounds. Its unique structure allows it to participate in a range of chemical reactions, facilitating the synthesis of new molecules with potential applications in different industries.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 1-(4-BROMOPHENYL)-1H-PYRAZOLE-4-CARBALDEHYDE is utilized as a key building block in the development of novel drugs. Its chemical properties may contribute to the design of innovative therapeutic agents, particularly those targeting specific biological pathways or receptors.
Used in Materials Science:
1-(4-BROMOPHENYL)-1H-PYRAZOLE-4-CARBALDEHYDE is employed as a component in the formulation of advanced materials. Its incorporation into material systems can lead to the development of new properties, such as improved stability, reactivity, or specific interactions with other substances, which can be beneficial in various applications.

Upstream product

• 497-19-8 sodium carbonate 
• 13788-92-6 1-(4-bromophenyl)-1H-pyrazole 
• 100-97-0 hexamethylenetetramine 
• 589-21-9 (4-bromophenyl)hydrazine 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 35344-95-7 1H-pyrazole-4-carbaldehyde 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 884850-98-0 methyl 1-(4-bromophenyl)-1H-pyrazole-4-carboxylate 

Relevant academic research and scientific papers

Antiangiogenic and antitumoral activity of LQFM126 prototype against B16F10 melanoma cells

Inhibition of mouse double minute 2 homolog (MDM2)-p53 interaction and reactivation of p53 signaling have been explored as effective anticancer therapeutic strategy. The potent and specific antitumor activity shown by Nutlins, first class of MDM2-p53 inhibitors discovered, has made these compounds potential antitumor candidates. To this end, we synthesized Nutlin-1 and Nutlin-2 analogs through molecular simplification and selected the compound with the most efficient antitumoral activity. Cytotoxicity of Nutlin-2 analog LQFM126 on B16F10 melanoma cells induced intense cytoplasmic vacuolization, reduction of cell size, chromatin condensation, cytoplasmic degeneration and nuclear fragmentation. LQFM126 antiproliferative effects mediated cell cycle retention in G0/G1 phase and increased the levels of cell cycle regulatory proteins p21 and p27. This Nutlin analog increased mitochondrial membrane potential, activated caspase-8, -9 and -3/7 and reduced VEGF levels in B16F10 cells. Therefore, LQFM126 promoted alterations suggestive of apoptosis, G0/G1 cell cycle arrest and suppression of angiogenesis through modulation of VEGF expression in B16F10 cells. Additionally, LQFM126 was classified as UN GHS category 4 (LD50 > 300–2000 mg/kg), suggesting it has low acute systemic toxicity. LQFM126 can be a promising prototype for anticancer therapy.

Electrophotocatalytic SNAr Reactions of Unactivated Aryl Fluorides at Ambient Temperature and Without Base

The electrophotocatalytic SNAr reaction of unactivated aryl fluorides at ambient temperature without strong base is demonstrated.

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE

The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

Chemoselective and regiospecific formylation of 1-phenyl-1H-pyrazoles through the duff reaction

The synthesis of formylated 1-phenyl-1H-pyrazole derivatives under the Duff reaction conditions is reported. Our results indicate that 1-phenyl-1H-pyrazole systems containing electron-withdrawing and electron-donating substituents at the phenyl moiety rea

Synthesis and antileishmanial activity of new 1-aryl-1H-pyrazole-4- carboximidamides derivatives

Chemotherapy for leishmaniasis, diseases caused by protozoa of the genus Leishmania, remains inefficient in several treatments. So there is a need to search for new drugs. In this work, we have synthesized 1-aryl-1H-pyrazole-4- carboximidamides derivatives and evaluated antileishmanial activities in vitro, as well as cytotoxic effects. Structure-activity relationship (SAR) studies were carried out with all the compounds of the series. Compound 2 showed an activity profile that can be improved through medicinal chemistry strategies.

Complete assignment of NMR data of 22 phenyl-1H-pyrazoles' derivatives

Complete assignment of 1H and 13C NMR chemical shifts and J(1H/1H and 1H/19F) coupling constants for 22 1-phenyl-1H-pyrazoles' derivates were performed using the concerted application of 1H 1D and 1H, 13C 2D gs-HSQC and gs-HMBC experiments. All 1-phenyl-1H-pyrazoles' derivatives were synthesized as described by Finar and co-workers. The formylated 1-phenyl-1H-pyrazoles' derivatives were performed under Duff's conditions. Copyright